Publication
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugFulvestrantcivic_curation1.00
- drugPalbociclibcivic_curation1.00
- drugRogaratinibcivic_curation1.00
- geneFGFR1civic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 33579347
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR1 Amplification2 | ||||||||
| (prognostic) | Malignant Breast Neoplasm | Prognostic | B | Supports Poor Outcome | 5 | accepted | EID12497Amplification of FGFR1 is one molecular alteration associated with hormonal resistance and relapse in breast cancer. Using two different patient data cohorts (H12O - patients diagnosed at Hospital 12 … (full text at CIViC) PMID 33579347 · Mouron et al., 2021 · Open in CIViC | civic |
| Fulvestrant + Palbociclib + RogaratinibCombination | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 5 | accepted | EID12503To determine if there is a causal relationship between hormonal blockade (a frequent treatment for tumors in the adjuvant setting) and FGFR1 amplification/overexpression, this study used two non-FGFR1… (full text at CIViC) PMID 33579347 · Mouron et al., 2021 · Open in CIViC | civic |